Hyaline fibromatosis syndrome inducing mutations in the ectodomain of anthrax toxin receptor 2 can be rescued by proteasome inhibitors.

Détails

Ressource 1Télécharger: BIB_27DB154B3E2F.P001.pdf (887.81 [Ko])
Etat: Public
Version: de l'auteur⸱e
ID Serval
serval:BIB_27DB154B3E2F
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Hyaline fibromatosis syndrome inducing mutations in the ectodomain of anthrax toxin receptor 2 can be rescued by proteasome inhibitors.
Périodique
Embo Molecular Medicine
Auteur⸱e⸱s
Deuquet J., Lausch E., Guex N., Abrami L., Salvi S., Lakkaraju A., Ramirez M.C., Martignetti J.A., Rokicki D., Bonafe L., Superti-Furga A., van der Goot F.G.
ISSN
1757-4684 (Electronic)
ISSN-L
1757-4676
Statut éditorial
Publié
Date de publication
2011
Volume
3
Numéro
4
Pages
208-221
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov'tPublication Status: ppublish
Résumé
Hyaline Fibromatosis Syndrome (HFS) is a human genetic disease caused by mutations in the anthrax toxin receptor 2 (or cmg2) gene, which encodes a membrane protein thought to be involved in the homeostasis of the extracellular matrix. Little is known about the structure and function of the protein or the genotype-phenotype relationship of the disease. Through the analysis of four patients, we identify three novel mutants and determine their effects at the cellular level. Altogether, we show that missense mutations that map to the extracellular von Willebrand domain or the here characterized Ig-like domain of CMG2 lead to folding defects and thereby to retention of the mutated protein in the endoplasmic reticulum (ER). Mutations in the Ig-like domain prevent proper disulphide bond formation and are more efficiently targeted to ER-associated degradation. Finally, we show that mutant CMG2 can be rescued in fibroblasts of some patients by treatment with proteasome inhibitors and that CMG2 is then properly transported to the plasma membrane and signalling competent, identifying the ER folding and degradation pathway components as promising drug targets for HFS.
Pubmed
Web of science
Open Access
Oui
Création de la notice
14/03/2011 14:35
Dernière modification de la notice
03/12/2020 17:53
Données d'usage